IC-OS Weekly Webinar - Managing hypertension during TKI therapy

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.

Ninian Lang is a Reader (Associate Professor) in Cardiology. He serves as an Honorary Consultant Cardiologist at the Queen Elizabeth University Hospital and the Beatson West of Scotland Cancer Centre. His clinical and academic work focuses on cardio-oncology and heart failure. He runs the West of Scotland cardio-oncology service and integrates this clinical practice with an active research programme. His clinical trial and translational research in cardio-oncology relates to vascular and myocardial injury induced by established and novel anti-cancer agents. His heart failure research includes clinical trials and clinical mechanistic studies of vascular and cardiac pharmacology. He is a graduate of the University of Edinburgh Medical School (BSc [Neuroscience], 1st class Hons, 1998; MBChB 2001, Annandale Gold Medal in Clinical Surgery). He undertook the majority of his clinical training in cardiology in Lothian. He was awarded the Bristol-Myers Squibb Cardiovascular Prize Fellowship to undertake his PhD research (University of Edinburgh; awarded 2009). He was subsequently appointed as Lecturer in Cardiology at the University of Edinburgh, followed by a fellowship in advanced heart failure and cardiac devices at the Scottish Advanced Heart Failure Service. He was appointed as a consultant cardiologist in 2014 before moving to a substantive position with the University of Glasgow. He is an Associate Editor of JACC:CardioOncology and previously held this position at Circulation:Heart Failure.

Dr. Rupal O'Quinn is an Assistant Professor of Clinical Medicine at the University of Pennsylvania, and the Director of Cardio-Oncology at Penn Presbyterian Medical Center. Dr. O’Quinn joined the faculty in 2015, and specializes in the field of cardio-oncology and multi-modality cardiovascular imaging that includes echocardiography and cardiac magnetic resonance. She is currently on the Research and Scientific Advisory Committee of the International Cardio-Oncology Society (ICOS), as well as a member of the Training in Cardio-Oncology and Cardio-Oncology Advocacy workgroups within the American College of Cardiology. Dr. O'Quinn completed a fellowship at the Hospital of the University of Pennsylvania in 2015, where she focused on Cardio-Oncology. Prior to that, Dr. O'Quinn completed a General Cardiology Fellowship at Beth Israel Deaconess Medical Center - Harvard University Medical School in Boston, Massachusetts with a focus in cardiovascular imaging. She is currently pursuing a Master of Healthcare Innovation at the University of Pennsylvania, with expected completion in May, 2023. Dr. O'Quinn completed her residency and chief medical residency at the University of Michigan Health Systems in Ann Arbor, Michigan. She attended medical school at the Rutgers Medical School/University of Medicine and Dentistry of New Jersey, and college at Boston University where she graduated Summa Cum Laude.

Dr Sandra Herrmann is Associate Professor of Medicine and a consultant in the Division of Nephrology and Hypertension at Mayo Clinic, Rochester, MN, USA. She obtained her medical degree from the Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil and completed her Internship and Nephrology fellowship at the PUCRS -Hospital Sao Lucas. She did her post-doctoral research fellowship and then completed her Internal Medicine Residency and Nephrology Fellowship at the Mayo Clinic, Rochester, MN, USA. She is a member of various scientific societies including American Society of Nephrology and a founding member of the American Society of Onconephrology (ASON). Her research interests are onco-nephrology, onco-hypertension, renovascular hypertensive disease and regenerative medicine in nephrology. She currently holds a NIH-NIDDK K08 career development award looking at hypoxic preconditioning to improve adipose-derived mesenchymal stem cells function from patients with hypertensive kidney disease. She is also the co-Chair of the Position Statement Committee for the ASON. Dr. Herrmann's research in onco-nephrology is focused on nephrotoxicity of cancer therapeutic agents such as immune checkpoint inhibitors, chimeric antigen receptor (CAR)-T cell therapy and other targeted cancer therapies such as VEGF/TKI inhibitors.